Anandamide

Last updated
Anandamide
Anandamide skeletal.svg
Names
Preferred IUPAC name
(5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
Other names
N-arachidonoylethanolamine
arachidonoylethanolamide
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
MeSH Anandamide
PubChem CID
UNII
  • InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15- Yes check.svgY
    Key: LGEQQWMQCRIYKG-DOFZRALJSA-N Yes check.svgY
  • InChI=1/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-
    Key: LGEQQWMQCRIYKG-DOFZRALJBA
  • O=C(NCCO)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC
  • CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCO
Properties
C22H37NO2
Molar mass 347.53 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Anandamide (ANA), also known as N-arachidonoylethanolamine (AEA), an N-acylethanolamine (NAE), is a fatty acid neurotransmitter. Anandamide was the first endocannabinoid to be discovered: it participates in the body's endocannabinoid system by binding to cannabinoid receptors, the same receptors that the psychoactive compound THC in cannabis acts on. Anandamide is found in nearly all tissues in a wide range of animals. [1] [2] Anandamide has also been found in plants, including small amounts in chocolate. [3] The name 'anandamide' is taken from the Sanskrit word ananda , which means "joy, bliss, delight", plus amide. [1] [4]

Contents

Anandamide is derived from the non-oxidative metabolism of arachidonic acid, an essential omega-6 fatty acid. It is synthesized from N-arachidonoyl phosphatidylethanolamine by multiple pathways. [5] It is degraded primarily by the fatty acid amide hydrolase (FAAH) enzyme, which converts anandamide into ethanolamine and arachidonic acid. As such, inhibitors of FAAH lead to elevated anandamide levels and are being pursued for therapeutic use. [6] [7]

Anandamide is also being explored for its role in diabetic neuropathy/neuropathy, as cannabinoids as well as exogenous or endogenous anandamide, demonstrate broad-spectrum antinociceptive properties in a model of painful diabetic neuropathy, mediated through peripheral activation of both cannabinoid receptors, i.e. CB1 and CB2, [8] [9] beside involvement of transient receptor vanilloid type-1 (TRPV1) channels in the pain modulation, as endovanilloid signalling modulates local pain, [10] as well as in reduction of inflammation associated with renal injury. [11]

Physiological functions

Anandamide's effects can occur in either the central or peripheral nervous system. These distinct effects are mediated primarily by CB1 cannabinoid receptors in the central nervous system, and CB2 cannabinoid receptors in the periphery. [12] The latter are mainly involved in functions of the immune system. Cannabinoid receptors were originally discovered as being sensitive to Δ9-tetrahydrocannabinol (Δ9-THC, commonly called THC), which is the primary psychoactive cannabinoid found in cannabis. The discovery of anandamide came from research into CB1 and CB2, as it was inevitable that a naturally occurring (endogenous) chemical would be found to affect these receptors.

Anandamide is also important for the implantation of the early stage embryo in its blastocyst form into the uterus. Therefore, cannabinoids such as Δ9-THC might influence processes during the earliest stages of human pregnancy. [13] Peak plasma anandamide occurs at ovulation and positively correlates with peak estradiol and gonadotrophin levels, suggesting that these may be involved in the regulation of anandamide levels. [14] Subsequently, anandamide has been proposed as a biomarker of infertility, but so far lacks any predictive values in order to be used clinically. [15]

The acute beneficial effects of exercise (termed as runner's high ) seem to be mediated by anandamide in mice. [16] Anandamide is the precursor of a class of physiologically active substances, the prostamides. [17] Anandamide was found in 2007 to inhibit the proliferation of certain human breast cancer cell lines in vitro. [18]

Anandamide is found in chocolate together with two substances that might mimic the effects of anandamide, N-oleoylethanolamine and N-linoleoylethanolamine. [19]

Additionally, anandamide and other endocannabinoids are found in the model organism Drosophila melanogaster (fruit fly), although no CB receptors have been found in any insects. [20] [21]

Effects on behavior

Both the CB1 and CB2 receptors (the bonding site of anandamide) seem to play a role in the identification of positive and negative interpretation of environment and setting. [22] In animal models, anandamide mediates the interpretation of stimulus; specifically, optimism and pessimism in the presence of an ambiguous cue. [23] Anandamide has been shown to impair working memory in rats, [24] while THC (the compound in cannabis that binds to the CB1 and CB2 receptors) also shows a deficit in working memory. [25]

This binding relationship of anandamide and the CB1/CB2 may affect neurotransmission of dopamine, serotonin, GABA, and glutamate. [26] There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC formulas. [27]

Anandamide injected directly into the forebrain reward-related brain structure nucleus accumbens enhances the pleasurable responses of rats to a rewarding sucrose taste, and enhances food intake as well. [28] Increasing anandamide seems to increase the intrinsic value of food, not necessarily by stimulation of appetite or hunger. [29]

Anandamide may affect hunger, sleep, pain modulation, working memory, identification of novelty, and interpretation of environment.[ citation needed ]

Synthesis and degradation

In humans, anandamide is biosynthesized from N-arachidonoyl phosphatidylethanolamine (NAPE). In turn, NAPE arises by transfer of arachidonic acid from lecithin to the free amine of cephalin through an N-acyltransferase enzyme. [30] [31] Anandamide synthesis from NAPE occurs via multiple pathways and includes enzymes such as phospholipase A2, phospholipase C and N-acetylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD). [5]

The crystal structure of NAPE-PLD in complex with phosphatidylethanolamine and deoxycholate shows how the cannabinoid anandamide is generated from membrane N-acylphosphatidylethanolamines (NAPEs), and reveals that bile acids – which are mainly involved in the absorption of lipids in the small intestine – modulate its biogenesis. [32]

Endogenous anandamide is present at very low levels and has a very short half-life due to the action of the enzyme fatty acid amide hydrolase (FAAH), which breaks it down into free arachidonic acid and ethanolamine. Studies of piglets show that dietary levels of arachidonic acid and other essential fatty acids affect the levels of anandamide and other endocannabinoids in the brain. [33] High fat diet feeding in mice increases levels of anandamide in the liver and increases lipogenesis. [34] Anandamide may be relevant to the development of obesity, at least in rodents.

Paracetamol (called acetaminophen in the US and Canada) is metabolically combined with arachidonic acid by FAAH to form AM404. [35] This metabolite of paracetamol is a potent agonist at the TRPV1 vanilloid receptor, a weak agonist at both CB1 and CB2 receptors, and an inhibitor of anandamide reuptake. As a result, anandamide levels in the body and brain are elevated. In this fashion, paracetamol acts as a pro-drug for a cannabimimetic metabolite. This action may be partially or fully responsible for the analgesic effects of paracetamol. [36] [37]

Endocannabinoid transporters for anandamide and 2-arachidonoylglycerol include the heat shock proteins (Hsp70s) and fatty acid binding proteins (FABPs). [38] [39]

It is found that anandamide prefers cholesterol and ceramide more than other membrane lipids, and cholesterol can behave as a binding partner for it, and following an initial interaction mediated by the establishment of a hydrogen bond, the endocannabinoid is attracted towards the membrane interior, where it forms a molecular complex with cholesterol after a functional conformation adaptation to the apolar membrane milieu, and from there, the complex is further directed to the cannabinoid receptor (CB1) and out. [40]

Research and production

Black pepper contains the alkaloid guineesine, which is an anandamide reuptake inhibitor. It may therefore increase anandamide's physiological effects. [41]

Low-dose anandamide has an anxiolytic effect, while in one study, high doses injected directly into the cerebral fluid of the brain of mice shows evident cell apoptosis (programmed cell death) in vitro as opposed to necrosis. [42] That being said, another study conducted under similar conditions demonstrated neuronal growth both in vitro and in vivo. [43]

Endocannabinoids may disturb homeostasis in several ways: by enhancing hunger sensations, encouraging increased food intake, and shifting energy balance towards energy storage. A resultant decrease in energy expenditure is observed. [44]

Another study with rats found that reductions in AEA signaling through FAAH overexpression within the basolateral complex of amygdala (BLA) appeared to reliably reduce measurements of anxiety and overall levels of corticosterone, a primary glucocorticoid in animals like birds, rodents, reptiles and amphibians responsible for energy regulation, immune and stress responses. This is similar to the main glucocorticoid cortisol in humans. Reduction of AEA in the BLA has been shown to suppress fear behavior and promote fear extinction. This suggests possible involvement of AEA intervention in the future for the treatment of psychological disorders. However, further work in this area of study is needed, as reduced anandamide signaling is believed at this moment to involve CB1 receptors as well as GABAergic and glutamatergic interactions. [45]

Cortical glutamatergic transmission may be modulated by endocannabinoids during stress and fear habituation. [46] Glutamatergic interaction in the BLA believed to be responsible for changes in anxiety, appears to normalize stress-induced anxiety-like behavior. A study indicated that infusion of the GluK1 receptor agonist ATPA into the BLA enhanced GABAergic neurotransmission, which is currently believed to have a large role in the reduction of anxiety symptoms. [47]

Additionally, the ECs, along with AEA, have been highlighted for their potential involvement in obesity development and harmful effects on lipid and glucose metabolism, which may contribute to insulin resistance and deficiency, both of which are major risk factors for developing type 2 diabetes mellitus. Blockade of CB1 receptors was found significantly to improve lipid resistance and lipid profile in obese subjects, but also has potential to increase fat accumulation through increased food intake, favored lipogenesis and reduced energy expenditure. This may affect downstream systems like the pancreas, liver, adipose tissue, and skeletal muscle, with inflammation and apoptosis in the case of the pancreas. CB1R inhibition with peripherally restricted antagonists and inverse agonists may aid in the treatment of diabetic neuropathy and neuropathy. CB2R agonists may show promise for the treatment of inflammation, which contributes to renal injury. [48]

AEA was associated with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), and liver fibrosis. Data suggests AEA as a marker for cardiometabolic disease and NAFLD severity. NAFLD can progress to more severe diseases, like NASH, cirrhosis, and hepatocellular carcinoma. [49]

A Scottish woman with a rare mutation in her FAAH gene that resulted in elevated anandamide levels was reported to be immune to anxiety, unable to experience fear, and insensitive to pain. The frequent burns and cuts she suffered due to her hypoalgesia healed more rapidly than was expected. [50] [51] [52]

Topical Anandamide was found to reduce peripheral neuropathic pain by interaction with peripheral cannabinoid receptors. [53]

The American Academy of Dermatology has named topical Anandamide a promising therapy for cutaneous lupus erythematosus. [54] [55]

See also

Related Research Articles

<span class="mw-page-title-main">Cannabinoid</span> Compounds found in cannabis

Cannabinoids are several structural classes of compounds found in the cannabis plant primarily and most animal organisms or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoactive compound in cannabis. Cannabidiol (CBD) is also a major constituent of temperate cannabis plants and a minor constituent in tropical varieties. At least 113 distinct phytocannabinoids have been isolated from cannabis, although only four have been demonstrated to have a biogenetic origin. It was reported in 2020 that phytocannabinoids can be found in other plants such as rhododendron, licorice and liverwort, and earlier in Echinacea.

<span class="mw-page-title-main">Cannabinoid receptor</span> Group of receptors to cannabinoid compounds

Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system of vertebrates– a class of cell membrane receptors in the G protein-coupled receptor superfamily. As is typical of G protein-coupled receptors, the cannabinoid receptors contain seven transmembrane spanning domains. Cannabinoid receptors are activated by three major groups of ligands:

<span class="mw-page-title-main">URB597</span> Chemical compound

URB597 (KDS-4103) is a relatively selective and irreversible inhibitor of the enzyme fatty acid amide hydrolase (FAAH). FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. URB597 has been found to elevate anandamide levels and have activity against neuropathic pain in a mouse model.

Fatty acid desaturases are a family of enzymes that convert saturated fatty acids into unsaturated fatty acids and polyunsaturated fatty acids. For the common fatty acids of the C18 variety, desaturases convert stearic acid into oleic acid. Other desaturases convert oleic acid into linolenic acid, which is the precursor to alpha-linolenic acid, gamma-linolenic acid, and eicosatrienoic acid.

<span class="mw-page-title-main">Endocannabinoid system</span> Biological system of neurotransmitters

The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, which are endogenous lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the vertebrate central nervous system and peripheral nervous system. The endocannabinoid system remains under preliminary research, but may be involved in regulating physiological and cognitive processes, including fertility, pregnancy, pre- and postnatal development, various activity of immune system, appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effects of cannabis. The ECS plays an important role in multiple aspects of neural functions, including the control of movement and motor coordination, learning and memory, emotion and motivation, addictive-like behavior and pain modulation, among others.

<span class="mw-page-title-main">Fatty-acid amide hydrolase 1</span> Mammalian protein found in Homo sapiens

Fatty-acid amide hydrolase 1 (FAAH) is a member of the serine hydrolase family of enzymes. It was first shown to break down anandamide (AEA), an N-acylethanolamine (NAE) in 1993. In humans, it is encoded by the gene FAAH.

<span class="mw-page-title-main">2-Arachidonoylglycerol</span> Chemical compound

2-Arachidonoylglycerol (2-AG) is an endocannabinoid, an endogenous agonist of the CB1 receptor and the primary endogenous ligand for the CB2 receptor. It is an ester formed from the omega-6 fatty acid arachidonic acid and glycerol. It is present at relatively high levels in the central nervous system, with cannabinoid neuromodulatory effects. It has been found in maternal bovine and human milk. The chemical was first described in 1994–1995, although it had been discovered some time before that. The activities of phospholipase C (PLC) and diacylglycerol lipase (DAGL) mediate its formation. 2-AG is synthesized from arachidonic acid-containing diacylglycerol (DAG).

<span class="mw-page-title-main">AM404</span> Active metabolite of paracetamol

AM404, also known as N-arachidonoylphenolamine, is an active metabolite of paracetamol (acetaminophen), responsible for all or part of its analgesic action and anticonvulsant effects. Chemically, it is the amide formed from 4-aminophenol and arachidonic acid.

<span class="mw-page-title-main">NAGly receptor</span> Protein-coding gene in the species Homo sapiens

N-Arachidonyl glycine receptor, also known as G protein-coupled receptor 18 (GPR18), is a protein that in humans is encoded by the GPR18 gene. Along with the other previously "orphan" receptors GPR55 and GPR119, GPR18 has been found to be a receptor for endogenous lipid neurotransmitters, several of which also bind to cannabinoid receptors. It has been found to be involved in the regulation of intraocular pressure.

<i>N</i>-Arachidonoyl dopamine Chemical compound

N-Arachidonoyl dopamine (NADA) is an endocannabinoid that acts as an agonist of the CB1 receptor and the transient receptor potential V1 (TRPV1) ion channel. NADA was first described as a putative endocannabinoid (agonist for the CB1 receptor) in 2000 and was subsequently identified as an endovanilloid (agonist for TRPV1) in 2002. NADA is an endogenous arachidonic acid based lipid found in the brain of rats, with especially high concentrations in the hippocampus, cerebellum, and striatum. It activates the TRPV1 channel with an EC50 of approximately of 50 nM which makes it the putative endogenous TRPV1 agonist.

<span class="mw-page-title-main">Oleoylethanolamide</span> Chemical compound

Oleoylethanolamide (OEA) is an endogenous peroxisome proliferator-activated receptor alpha (PPAR-α) agonist. It is a naturally occurring ethanolamide lipid that regulates feeding and body weight in vertebrates ranging from mice to pythons.

<i>N</i>-Acylethanolamine Class of chemical compounds

An N-acylethanolamine (NAE) is a type of fatty acid amide where one of several types of acyl groups is linked to the nitrogen atom of ethanolamine, and highly metabolic formed by intake of essential fatty acids through diet by 20:4, n-6 and 22:6, n-3 fatty acids, and when the body is physically and psychologically active,. The endocannabinoid signaling system (ECS) is the major pathway by which NAEs exerts its physiological effects in animal cells with similarities in plants, and the metabolism of NAEs is an integral part of the ECS, a very ancient signaling system, being clearly present from the divergence of the protostomian/deuterostomian, and even further back in time, to the very beginning of bacteria, the oldest organisms on Earth known to express phosphatidylethanolamine, the precursor to endocannabinoids, in their cytoplasmic membranes. Fatty acid metabolites with affinity for CB receptors are produced by cyanobacteria, which diverged from eukaryotes at least 2000 million years ago (MYA), by brown algae which diverged about 1500 MYA, by sponges, which diverged from eumetazoans about 930 MYA, and a lineages that predate the evolution of CB receptors, as CB1 – CB2 duplication event may have occurred prior to the lophotrochozoan-deuterostome divergence 590 MYA. Fatty acid amide hydrolase (FAAH) evolved relatively recently, either after the evolution of fish 400 MYA, or after the appearance of mammals 300 MYA, but after the appearance of vertebrates. Linking FAAH, vanilloid receptors (VR1) and anandamide implies a coupling among the remaining ‘‘older’’ parts of the endocannabinoid system, monoglyceride lipase (MGL), CB receptors, that evolved prior to the metazoan–bilaterian divergence, but were secondarily lost in the Ecdysozoa, and 2-Arachidonoylglycerol (2-AG).

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, and lipid modulator PEA has been studied in in vitro and in vivo systems using exogenously added or dosed compound; there is evidence that it binds to a nuclear receptor, through which it exerts a variety of biological effects, some related to chronic inflammation and pain.

<span class="mw-page-title-main">Abnormal cannabidiol</span> Synthetic, cannabinoid-like compound

Abnormal cannabidiol (Abn-CBD) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects.

RVD-Hpα (pepcan-12) is an endogenous neuropeptide found in human and mammalian brain, which was originally proposed to act as a selective agonist for the CB1 cannabinoid receptor. It is a 12-amino acid polypeptide having the amino acid sequence Arg-Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His and is an N-terminal extended form of hemopressin, a 9-AA polypeptide derived from the α1 subunit of hemoglobin which has previously been shown to act as a CB1 inverse agonist. All three polypeptides have been isolated from various mammalian species, with RVD-Hpα being one of the more abundant neuropeptides expressed in mouse brain, and these neuropeptides represent a new avenue for cannabinoid research distinct from the previously known endogenous lipid-derived cannabinoid agonists such as anandamide. Recently it was shown that RVD-Hpα (also called Pepcan-12) is a potent negative allosteric modulator at CB1 receptors, together with other newly described N-terminally extended peptides (pepcans).

<i>N</i>-Arachidonylglycine Chemical compound

N-Arachidonylglycine (NAGly) is a carboxylic metabolite of the endocannabinoid anandamide (AEA). Since it was first synthesized in 1996, NAGly has been a primary focus of the relatively contemporary field of lipidomics due to its wide range of signaling targets in the brain, the immune system and throughout various other bodily systems. In combination with 2‐arachidonoyl glycerol (2‐AG), NAGly has enabled the identification of a family of lipids often referred to as endocannabinoids. Recently, NAGly has been found to bind to G-protein coupled receptor 18 (GPR18), the putative abnormal cannabidiol receptor. NaGly is an endogenous inhibitor of fatty acid amide hydrolase (FAAH) and thereby increases the ethanolamide endocannabinoids AEA, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) levels. NaGly is found throughout the body and research on its explicit functions is ongoing.

The endocannabinoid transporters (eCBTs) are transport proteins for the endocannabinoids. Most neurotransmitters are water-soluble and require transmembrane proteins to transport them across the cell membrane. The endocannabinoids on the other hand, are non-charged lipids that readily cross lipid membranes. However, since the endocannabinoids are water immiscible, protein transporters have been described that act as carriers to solubilize and transport the endocannabinoids through the aqueous cytoplasm. These include the heat shock proteins (Hsp70s) and fatty acid-binding proteins for anandamide (FABPs). FABPs such as FABP1, FABP3, FABP5, and FABP7 have been shown to bind endocannabinoids. FABP inhibitors attenuate the breakdown of anandamide by the enzyme fatty acid amide hydrolase (FAAH) in cell culture. One of these inhibitors (SB-FI-26), isolated from a virtual library of a million compounds, belongs to a class of compounds that act as an anti-nociceptive agent with mild anti-inflammatory activity in mice. These truxillic acids and their derivatives have been known to have anti-inflammatory and anti-nociceptive effects in mice and are active components of a Chinese herbal medicine used to treat rheumatism and pain in human. The blockade of anandamide transport may, at least in part, be the mechanism through which these compounds exert their anti-nociceptive effects.

<span class="mw-page-title-main">Cannabis in pregnancy</span> Effects of cannabis consumption during pregnancy

Cannabis consumption in pregnancy may or may not be associated with restrictions in growth of the fetus, miscarriage, and cognitive deficits. The American College of Obstetricians and Gynecologists recommended that cannabis use be stopped before and during pregnancy. There has not been any official link between birth defects and marijuana use. Cannabis is the most commonly used illicit substance among pregnant women.

<i>N</i>-Acylamides

N-acyl amides are a general class of endogenous fatty acid compounds characterized by a fatty acyl group linked to a primary amine metabolite by an amide bond. Broadly speaking, N-acyl amides fall into several categories: amino acid conjugates, neurotransmitter conjugates, ethanolamine conjugates, and taurine conjugates. N-acyl amides have pleiotropic signaling functions in physiology, including in cardiovascular function, metabolic homeostasis, memory, cognition, pain, motor control and others. Initial attention focused on N-acyl amides present in mammalian organisms, however recently lipid signaling systems consisting of N-acyl amides have also been found to be present in invertebrates, such as Drosophila melanogaster. N-acyl amides play important roles in many biochemical pathways involved in a variety of physiological and pathological processes, as well as the metabolic enzymes, transporters, and receptors that regulate their signaling.

An endocannabinoid enhancer (eCBE) is a type of cannabinoidergic drug that enhances the activity of the endocannabinoid system by increasing extracellular concentrations of endocannabinoids. Examples of different types of eCBEs include fatty acid amide hydrolase (FAAH) inhibitors, monoacylglycerol lipase (MAGL) inhibitors, and endocannabinoid transporter (eCBT) inhibitors. An example of an actual eCBE is AM404, the active metabolite of the analgesic paracetamol and a dual FAAH inhibitor and eCBRI.

References

  1. 1 2 Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (December 1992). "Isolation and structure of a brain constituent that binds to the cannabinoid receptor". Science. 258 (5090): 1946–1949. Bibcode:1992Sci...258.1946D. doi:10.1126/science.1470919. PMID   1470919.
  2. ↑ Martin BR, Mechoulam R, Razdan RK (1999). "Discovery and characterization of endogenous cannabinoids". Life Sciences. 65 (6–7): 573–595. doi:10.1016/S0024-3205(99)00281-7. PMID   10462059.
  3. ↑ di Tomaso E, Beltramo M, Piomelli D (August 1996). "Brain cannabinoids in chocolate". Nature (Submitted manuscript). 382 (6593): 677–678. Bibcode:1996Natur.382..677D. doi:10.1038/382677a0. PMID   8751435. S2CID   4325706.
  4. ↑ Mechoulam R, Fride E (1995). "The unpaved road to the endogenous brain cannabinoid ligands, the anandamides". In Pertwee RG (ed.). Cannabinoid receptors. Boston: Academic Press. pp. 233–258. ISBN   978-0-12-551460-6.
  5. 1 2 Wang J, Ueda N (September 2009). "Biology of endocannabinoid synthesis system". Prostaglandins & Other Lipid Mediators. 89 (3–4): 112–119. doi:10.1016/j.prostaglandins.2008.12.002. PMID   19126434.
  6. ↑ Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V (2009). "The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs". International Review of Neurobiology. 85: 57–72. doi:10.1016/S0074-7742(09)85005-8. ISBN   9780123748935. PMID   19607961.
  7. ↑ Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA (April 2010). "Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality". Life Sciences. 86 (15–16): 615–623. doi:10.1016/j.lfs.2009.06.003. PMC   2848893 . PMID   19527737.
  8. ↑ Schreiber, Anne K.; Neufeld, Manuele; Jesus, Carlos H. A.; Cunha, Joice M. (2012-12-01). "Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats". Neuropharmacology. 63 (8): 1286–1297. doi:10.1016/j.neuropharm.2012.08.009. ISSN   0028-3908. PMID   22959964. S2CID   801794.
  9. ↑ Ellington, Heather C; Cotter, Mary A; Cameron, Norman E; Ross, Ruth A (2002-06-01). "The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats". Neuropharmacology. 42 (7): 966–975. doi:10.1016/S0028-3908(02)00040-0. ISSN   0028-3908. PMID   12069907. S2CID   29219641.
  10. ↑ Silva, M.; Martins, D.; Charrua, A.; Piscitelli, F.; Tavares, I.; Morgado, C.; Di Marzo, V. (2016-08-01). "Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy". Neuropharmacology. 107: 49–57. doi:10.1016/j.neuropharm.2016.03.007. ISSN   0028-3908. PMID   26965218. S2CID   24034722.
  11. ↑ Schreiber, Anne K.; Neufeld, Manuele; Jesus, Carlos H. A.; Cunha, Joice M. (2012-12-01). "Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats". Neuropharmacology. 63 (8): 1286–1297. doi:10.1016/j.neuropharm.2012.08.009. ISSN   0028-3908. PMID   22959964. S2CID   801794.
  12. ↑ Pacher P, Bátkai S, Kunos G (September 2006). "The endocannabinoid system as an emerging target of pharmacotherapy". Pharmacological Reviews. 58 (3): 389–462. doi:10.1124/pr.58.3.2. PMC   2241751 . PMID   16968947.
  13. ↑ Piomelli D (January 2004). "THC: moderation during implantation". Nature Medicine. 10 (1): 19–20. doi:10.1038/nm0104-19. PMID   14702623. S2CID   29207064.
  14. ↑ El-Talatini MR, Taylor AH, Konje JC (April 2010). "The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle". Fertility and Sterility. 93 (6): 1989–1996. doi: 10.1016/j.fertnstert.2008.12.033 . PMID   19200965.
  15. ↑ Rapino C, Battista N, Bari M, Maccarrone M (2014). "Endocannabinoids as biomarkers of human reproduction". Human Reproduction Update. 20 (4): 501–516. doi: 10.1093/humupd/dmu004 . PMID   24516083.
  16. ↑ Fuss J, Steinle J, Bindila L, Auer MK, Kirchherr H, Lutz B, Gass P (October 2015). "A runner's high depends on cannabinoid receptors in mice". Proceedings of the National Academy of Sciences of the United States of America. 112 (42): 13105–13108. Bibcode:2015PNAS..11213105F. doi: 10.1073/pnas.1514996112 . PMC   4620874 . PMID   26438875.
  17. ↑ Woodward DF, Liang Y, Krauss AH (February 2008). "Prostamides (prostaglandin-ethanolamides) and their pharmacology". British Journal of Pharmacology. 153 (3): 410–419. doi:10.1038/sj.bjp.0707434. PMC   2241799 . PMID   17721551.
  18. ↑ De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (July 1998). "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation". Proceedings of the National Academy of Sciences of the United States of America. 95 (14): 8375–8380. Bibcode:1998PNAS...95.8375D. doi: 10.1073/pnas.95.14.8375 . PMC   20983 . PMID   9653194.
  19. ↑ di Tomaso E, Beltramo M, Piomelli D (August 1996). "Brain cannabinoids in chocolate". Nature. 382 (6593): 677–678. Bibcode:1996Natur.382..677D. doi:10.1038/382677a0. PMID   8751435. S2CID   4325706.
  20. ↑ Jeffries KA, Dempsey DR, Behari AL, Anderson RL, Merkler DJ (May 2014). "Drosophila melanogaster as a model system to study long-chain fatty acid amide metabolism". FEBS Letters. 588 (9): 1596–1602. doi:10.1016/j.febslet.2014.02.051. PMC   4023565 . PMID   24650760.
  21. ↑ McPartland J, Di Marzo V, De Petrocellis L, Mercer A, Glass M (August 2001). "Cannabinoid receptors are absent in insects". The Journal of Comparative Neurology. 436 (4): 423–429. doi:10.1002/cne.1078. PMID   11447587. S2CID   25765136.
  22. ↑ Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R (June 2013). "Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences". Neuropsychology Review. 23 (2): 117–137. doi:10.1007/s11065-012-9222-1. PMC   3593817 . PMID   23129391.
  23. ↑ Kregiel J, Malek N, Popik P, Starowicz K, Rygula R (February 2016). "Anandamide mediates cognitive judgement bias in rats". Neuropharmacology. 101: 146–153. doi:10.1016/j.neuropharm.2015.09.009. PMID   26363193. S2CID   39931221.
  24. ↑ Mallet P, Beninger R (May 1996). "The endogenous cannabinoid receptor agonist anandamide impairs memory in rats". Behavioural Pharmacology. 7 (3): 276–284. doi:10.1097/00008877-199605000-00008. ISSN   0955-8810. S2CID   143995667.
  25. ↑ Calabrese EJ, Rubio-Casillas A (May 2018). "Biphasic effects of THC in memory and cognition". European Journal of Clinical Investigation. 48 (5): e12920. doi: 10.1111/eci.12920 . PMID   29574698. S2CID   4333071.
  26. ↑ Fantegrossi WE, Wilson CD, Berquist MD (February 2018). "Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems". Drug Metabolism Reviews. 50 (1): 65–73. doi:10.1080/03602532.2018.1428343. PMC   6419500 . PMID   29385930.
  27. ↑ Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J (January 2020). "Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review". BMC Psychiatry. 20 (1): 24. doi: 10.1186/s12888-019-2409-8 . PMC   6966847 . PMID   31948424.
  28. ↑ Mahler SV, Smith KS, Berridge KC (November 2007). "Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward". Neuropsychopharmacology. 32 (11): 2267–2278. doi: 10.1038/sj.npp.1301376 . PMID   17406653. S2CID   14549059.
  29. ↑ Williams CM, Kirkham TC (June 2002). "Observational analysis of feeding induced by Δ9-THC and anandamide". Physiology & Behavior. 76 (2): 241–250. doi:10.1016/S0031-9384(02)00725-4. PMID   12044596. S2CID   144137807.
  30. ↑ Natarajan V, Reddy PV, Schmid PC, Schmid HH (August 1982). "N-Acylation of ethanolamine phospholipids in canine myocardium". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 712 (2): 342–355. doi:10.1016/0005-2760(82)90352-6. PMID   7126608.
  31. ↑ Cadas H, di Tomaso E, Piomelli D (February 1997). "Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain". The Journal of Neuroscience. 17 (4): 1226–1242. doi: 10.1523/JNEUROSCI.17-04-01226.1997 . PMC   6793739 . PMID   9006968.
  32. ↑ Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G (March 2015). "Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids". Structure. 23 (3): 598–604. doi:10.1016/j.str.2014.12.018. PMC   4351732 . PMID   25684574.
  33. ↑ Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V (May 2001). "Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets". Proceedings of the National Academy of Sciences of the United States of America. 98 (11): 6402–6406. Bibcode:2001PNAS...98.6402B. doi: 10.1073/pnas.101119098 . PMC   33480 . PMID   11353819.
  34. ↑ Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, et al. (May 2005). "Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity". The Journal of Clinical Investigation. 115 (5): 1298–1305. doi:10.1172/JCI23057. PMC   1087161 . PMID   15864349.
  35. ↑ Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al. (September 2005). "Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system". The Journal of Biological Chemistry. 280 (36): 31405–31412. doi: 10.1074/jbc.M501489200 . PMID   15987694.
  36. ↑ Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S (September 2006). "Paracetamol: new vistas of an old drug". CNS Drug Reviews. 12 (3–4): 250–275. doi:10.1111/j.1527-3458.2006.00250.x. PMC   6506194 . PMID   17227290.
  37. ↑ Sinning C, Watzer B, Coste O, Nüsing RM, Ott I, Ligresti A, et al. (December 2008). "New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide". Journal of Medicinal Chemistry. 51 (24): 7800–7805. doi:10.1021/jm800807k. PMID   19053765.
  38. ↑ Kaczocha M, Glaser ST, Deutsch DG (April 2009). "Identification of intracellular carriers for the endocannabinoid anandamide". Proceedings of the National Academy of Sciences of the United States of America. 106 (15): 6375–6380. Bibcode:2009PNAS..106.6375K. doi: 10.1073/pnas.0901515106 . PMC   2669397 . PMID   19307565.
  39. ↑ Oddi S, Fezza F, Pasquariello N, D'Agostino A, Catanzaro G, De Simone C, et al. (June 2009). "Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins". Chemistry & Biology. 16 (6): 624–632. doi:10.1016/j.chembiol.2009.05.004. PMID   19481477.
  40. ↑ Di Scala C, Fantini J, Yahi N, Barrantes FJ, Chahinian H (May 2018). "Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter". Biomolecules. 8 (2): 31. doi: 10.3390/biom8020031 . PMC   6022874 . PMID   29789479.
  41. ↑ Nicolussi S, Viveros-Paredes JM, Gachet MS, Rau M, Flores-Soto ME, Blunder M, Gertsch J (February 2014). "Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice". Pharmacological Research. 80: 52–65. doi:10.1016/j.phrs.2013.12.010. PMID   24412246.
  42. ↑ Cernak I, Vink R, Natale J, Stoica B, Lea PM, Movsesyan V, et al. (May 2004). "The "dark side" of endocannabinoids: a neurotoxic role for anandamide". Journal of Cerebral Blood Flow and Metabolism. 24 (5): 564–578. doi: 10.1097/00004647-200405000-00011 . PMID   15129189.
  43. ↑ Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, et al. (May 2003). "Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases". The Journal of Neuroscience. 23 (10): 4127–4133. doi: 10.1523/JNEUROSCI.23-10-04127.2003 . PMC   6741091 . PMID   12764100.
  44. ↑ Schulz, Piotr; Hryhorowicz, Szymon; Rychter, Anna Maria; Zawada, Agnieszka; Słomski, Ryszard; Dobrowolska, Agnieszka; Krela-Kaźmierczak, Iwona (2021-01-26). "What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?". Nutrients. 13 (2): 373. doi: 10.3390/nu13020373 . ISSN   2072-6643. PMC   7911032 . PMID   33530406.
  45. ↑ Morena, Maria; Aukema, Robert J.; Leitl, Kira D.; Rashid, Asim J.; Vecchiarelli, Haley A.; Josselyn, Sheena A.; Hill, Matthew N. (2019-02-13). "Upregulation of Anandamide Hydrolysis in the Basolateral Complex of Amygdala Reduces Fear Memory Expression and Indices of Stress and Anxiety". The Journal of Neuroscience. 39 (7): 1275–1292. doi:10.1523/JNEUROSCI.2251-18.2018. ISSN   0270-6474. PMC   6381235 . PMID   30573646.
  46. ↑ Kamprath, K.; Plendl, W.; Marsicano, G.; Deussing, J. M.; Wurst, W.; Lutz, B.; Wotjak, C. T. (March 2009). "Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling". Genes, Brain and Behavior. 8 (2): 203–211. doi: 10.1111/j.1601-183X.2008.00463.x . PMID   19077175. S2CID   21922344.
  47. ↑ Masneuf, Sophie; Lowery-Gionta, Emily; Colacicco, Giovanni; Pleil, Kristen E.; Li, Chia; Crowley, Nicole; Flynn, Shaun; Holmes, Andrew; Kash, Thomas (October 2014). "Glutamatergic mechanisms associated with stress-induced amygdala excitability and anxiety-related behavior". Neuropharmacology. 85: 190–197. doi:10.1016/j.neuropharm.2014.04.015. PMC   4170856 . PMID   24796255.
  48. ↑ Gruden, G; Barutta, F; Kunos, G; Pacher, P (April 2016). "Role of the endocannabinoid system in diabetes and diabetic complications: Role of endocannabinoid system in diabetes". British Journal of Pharmacology. 173 (7): 1116–1127. doi:10.1111/bph.13226. PMC   4941127 . PMID   26076890.
  49. ↑ Kimberly, W. Taylor; O'Sullivan, John F.; Nath, Anjali K.; Keyes, Michelle; Shi, Xu; Larson, Martin G.; Yang, Qiong; Long, Michelle T.; Vasan, Ramachandran; Peterson, Randall T.; Wang, Thomas J.; Corey, Kathleen E.; Gerszten, Robert E. (2017-05-04). "Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis". JCI Insight. 2 (9): e92989. doi:10.1172/jci.insight.92989. ISSN   2379-3708. PMC   5414569 . PMID   28469090.
  50. ↑ Habib AM, Okorokov AL, Hill MN, Bras JT, Lee MC, Li S, et al. (August 2019). "Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity". British Journal of Anaesthesia. 123 (2): e249–e253. doi: 10.1016/j.bja.2019.02.019 . PMC   6676009 . PMID   30929760.
  51. ↑ Murphy H (28 March 2019). "At 71, She's Never Felt Pain or Anxiety. Now Scientists Know Why". The New York Times. Retrieved 29 March 2019.
  52. ↑ Sample I (28 March 2019). "Scientists find genetic mutation that makes woman feel no pain". The Guardian. Retrieved 29 March 2019.
  53. ↑ Police, Anitha; Shankar, Vijay Kumar; Pandey, Pankaj; Rangappa, Srinath; Doerksen, Robert J.; Narasimha Murthy, S. (2023). "Novel topical anandamide formulation for alleviating peripheral neuropathic pain". International Journal of Pharmaceutics. 641: 123085. doi:10.1016/j.ijpharm.2023.123085. PMID   37245739. S2CID   258942838.
  54. ↑ "AAD ePosters".
  55. ↑ "A New Treatment in a New Package for Cutaneous Lupus Erythematosus". 19 March 2023.